Medicines regulator set to give Alzheimer’s drug green light
Lecanemab works by binding to amyloid, a protein which builds up in the brains of people living with Alzheimer’s disease.
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.The UK’s medicines regulator is set to approve a drug that has been shown to slow the progression of Alzheimer’s disease.
Lecanemab, developed by pharmaceutical company Eisai, is a targeted antibody treatment that binds to amyloid, a protein which builds up in the brains of people living with Alzheimer’s disease.
It is designed to help clear the build-up and slow down cognitive decline in people with the condition and is given to patients via an intravenous drip fortnightly.
The decision from the Medicines and Healthcare products Regulatory Agency (MHRA) is set to be announced shortly, but it is understood to have approved the treatment.
It will also need the green light from health service spending watchdog the National Institute for Health and Care Excellence (Nice) before it is rolled out on the NHS in England.
Lecanemab is already licensed in the US, where it costs about £20,000 per patient per year, although it was rejected by the European Medicines Agency (EMA) in late July.
The EMA said the benefits of lecanemab did not counterbalance the risk of people suffering serious side-effects such as bleeding and swelling in the brain.
It also said the effects of the drug on delaying cognitive decline were small.
A similar drug called donanemab, which is developed by Eli Lilly, is also being assessed for approval in the UK by medicine regulators.
NHS England estimates between 50,000 and 280,000 patients might be eligible for the new treatments.
Prior to being given the drugs, they will need to have a baseline MRI scan and then either a Pet-CT scan or lumbar puncture to confirm Alzheimer’s.